Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman(Johns Hopkins University), Richard E. Chaisson(Johns Hopkins University), J Grosset(Johns Hopkins University), John Bernardo(Boston University), Grace Muzanye(Case Western Reserve University), Nesri Padayatchi(Centre for the AIDS Programme of Research in South Africa), John L. Johnson(University of Pennsylvania), Maria Leus(Rutgers, The State University of New Jersey), Dick Menzies(McGill University), Margarita E. Villarino(Centers for Disease Control and Prevention), Andrew Vernon(Centers for Disease Control and Prevention), Lorna Bozeman(Centers for Disease Control and Prevention), Gina Maltas(Johns Hopkins University), Charles M. Heilig(Centers for Disease Control and Prevention), Eric Nuermberger(Johns Hopkins University), Elizabeth Guy(Baylor College of Medicine), Shurjeel Choudhri(Case Western Reserve University), Priya Guyadeen(Westat (United States)), Stefan Goldberg
Cited by 266
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|PubMed|2010|1.1k